• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/19/21 1:08:44 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNPX alert in real time by email
    SC 13G/A 1 gnpx-sc13ga_021221.htm AMENDMENT TO FORM SC 13G
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

    Genprex, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value

    (Title of Class of Securities)

     

    372446104

    (CUSIP Number)

     
    February 12, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 2 of 8

     

    CUSIP No. 372446104    

     

    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    2,400,000 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    2,400,000 shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,400,000 shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.1%

     
    12

    TYPE OF REPORTING PERSON

    IA, PN

     
             
     

     

    (1)

    Based on 47,276,764 shares of Common Stock outstanding as of February 8, 2021 as set forth in the Issuer’s Prospectus Supplement 424(b)(5) filed with the Securities and Exchange Commission on February 10, 2021.

     

    Page 3 of 8

     

    CUSIP No. 372446104    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    2,400,000 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    2,400,000 Shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,400,000 Shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.1%

     
    12

    TYPE OF REPORTING PERSON

    PN

     
             
    (1)Based on 47,276,764 shares of Common Stock outstanding as of February 8, 2021 as set forth in the Issuer’s Prospectus Supplement 424(b)(5) filed with the Securities and Exchange Commission on February 10, 2021.

     

    Page 4 of 8

     

    CUSIP No. 372446104    

     

    1

    NAME OF REPORTING PERSONS

    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    2,400,000 Shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    2,400,000 Shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,400,000 Shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.1%

     
    12

    TYPE OF REPORTING PERSON

    OO

     
             
     

    (1)Based on 47,276,764 shares of Common Stock outstanding as of February 8, 2021 as set forth in the Issuer’s Prospectus Supplement 424(b)(5) filed with the Securities and Exchange Commission on February 10, 2021.

     

    Page 5 of 8

     

    CUSIP No. 372446104    

     

    Item 1(a).   Name of Issuer:                                                         Genprex , Inc. (the “Issuer”)
         
    Item 1(b).  

    Address of Issuer’s Principal Executive Offices: 1601 Trinity Street, #3.312.09

    Austin, TX 78712

         
    Item 2(a).  

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, the Fund.

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
        The address of the principal business office of each of the reporting persons is
    152 West 57th Street, FL 20, New York, NY 10019
         
    Item 2(c).   Citizenship:
        See Item 4 on the cover page(s) hereto.
         
    Item 2(d).   Title of Class of Securities:
        Common Stock, $0.001 par value (“Common Stock”)
         
    Item 2(e).   CUSIP Number: 372446104

     

    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
       
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    Page 6 of 8

     

           
    CUSIP No. 372446104      
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
     

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 47,276,764 shares of Common Stock outstanding as of February 8, 2021 as set forth in the Issuer’s Prospectus Supplement 424(b)(5) filed with the Securities and Exchange Commission on February 10, 2021.

     

    Page 7 of 8

     

    CUSIP No . 372446104    

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: February 19, 2021  

           
      Altium Capital Management, LP  
           
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: CEO  
           
      Altium Growth Fund, LP  
           
      By: Altium Growth GP, LLC  
      Its: General Partner  
           
      Signature: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member of Altium Growth GP, LLC  
           
      Altium Growth GP, LLC  
         
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member  

     

    Page 8 of 8

     

    EXHIBIT INDEX

     

    EXHIBIT 1: Joint Acquisition Statement Pursuant to Section 240.13d-1(k)
       
      Members of Group

     

    Get the next $GNPX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNPX
    SEC Filings

    See more
    • SEC Form S-1 filed by Genprex Inc.

      S-1 - Genprex, Inc. (0001595248) (Filer)

      5/14/25 8:51:24 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Genprex Inc.

      10-Q - Genprex, Inc. (0001595248) (Filer)

      5/12/25 4:31:16 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Genprex, Inc. (0001595248) (Filer)

      5/7/25 7:30:09 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Berger Mark Stanley covered exercise/tax liability with 585 shares, decreasing direct ownership by 3% to 22,471 units (SEC Form 4)

      4 - Genprex, Inc. (0001595248) (Issuer)

      2/19/25 8:01:36 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO and CFO Confer Ryan M. covered exercise/tax liability with 395 shares, decreasing direct ownership by 1% to 38,743 units (SEC Form 4)

      4 - Genprex, Inc. (0001595248) (Issuer)

      2/19/25 8:00:01 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Moreno Toscano Jose Antonio was granted 4,750 shares, increasing direct ownership by 153% to 7,845 units (SEC Form 4)

      4 - Genprex, Inc. (0001595248) (Issuer)

      12/6/24 5:55:11 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

      Presentation to Highlight Genprex's Study of Reqorsa® Gene Therapy in Combination with Tecentriq® for the Treatment of Extensive Stage Small Cell Lung Cancer AUSTIN, Texas, May 29, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has been selected to present at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago, Illinois and online. Ge

      5/29/25 7:00:00 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

      Novel Gene Therapy is Addressing Both Type 1 and Type 2 Diabetes AUSTIN, Texas, May 28, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that its research collaborators presented positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate, in an oral presentation at the American Society of Gene and Cell Therapy's (ASGCT) 28th Annual Meeting which took place May 13-17, 2025 in New Orleans, Louisiana.

      5/28/25 7:00:00 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

      Advances Relationship and Collaboration with the University of Pittsburgh of the Commonwealth System of Higher Education AUSTIN, Texas, May 7, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that following the recent completion of its two-year Sponsored Research Agreement (SRA) with the University of Pittsburgh of the Commonwealth System of Higher Education (Pitt) to study Type 1 diabetes (T1D) and Type 2 diabetes (T2D), the parties have entered into a new SRA to study GPX-002, the Company's gene therapy for diabetes, in T1

      5/7/25 7:00:00 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Genprex Inc.

      SC 13G/A - Genprex, Inc. (0001595248) (Subject)

      10/24/24 12:23:37 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Genprex Inc.

      SC 13G - Genprex, Inc. (0001595248) (Subject)

      10/22/24 12:01:59 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Genprex Inc.

      SC 13G - Genprex, Inc. (0001595248) (Subject)

      10/3/24 10:09:50 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • National Securities initiated coverage on Genprex with a new price target

      National Securities initiated coverage of Genprex with a rating of Buy and set a new price target of $7.00

      1/26/21 7:48:53 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

      Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas, May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company's co-founder and previous Chairman Rodney Varner. Prior to his appointment as Chairman,

      5/13/24 8:31:00 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

      Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer AUSTIN, Texas, Aug. 22, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the appointment of Suzanne Thornton-Jones, Ph.D. as Senior Vice President, Regulatory Affairs. Dr. Thornton-Jones will leverage her regulatory expertise to guide and oversee the Company's regulatory submissions and strategy

      8/22/23 7:30:00 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care